On the contrary, the same LNP technology, in particular the SNALP subfamily, was successfully used for the cure of TransThyRetin (TTR)-mediated amyloidosis through the development of ALN-TTR02 or for the treatment of solid tumors, this through ALN-VSP02 formulation, which has passed the phase I of clinical trials. This evidence concerns the gene ARLN and amyloidosis.